LDC exits £178m global drug research group

MID-market private equity firm LDC’s Manchester office has completed the exit of Lancashire-based Synexus, a global research site group which provides patient recruitment and treatment services in support of drug research for clinical trials, in a deal which values the business at £178m.

Synexus has been acquired by Jaguar Holding Company Luxembourg SARL and the transaction generates a 2.3x money multiple for LDC.

Chorley-headquartered Synexus is one of the only global patient enrolment and investigato... For the full story register now for free or login below...

Close